Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
ESMO Breast Cancer Preceptorship
Singapore November 2018
(Neo) Adjuvant Endocrine Therapy and
Special Populations
Prudence Francis MD
Peter MacCallum Cancer Centre
Melbourne, Australia
Dr Prudence Francis
Conflict of Interest
Honoraria: AstraZeneca, Novartis
Overseas Lecture (travel): Pfizer
All our patients are special
but some groups deserve special attention
(Neo) Adjuvant Endocrine Therapy
Special Populations
• Male Breast Cancer
• Elderly - Senior
• Lobular histology
• Very Young Women
Male Breast Cancer: Pink Ribbon Blues
Francis P, Ann Oncol 2018
Male Breast Cancer
• Men in general population have ~ 0.1% chance
of developing breast cancer
• Slightly < 1% of all breast cancers occur in men
• Male breast cancer is typically diagnosed at a
5-10 year older age than in women (median
age of diagnosis in men late 60’s)
International Male Breast Cancer Program
Breast Cancer Phenotype
• Male breast cancer typically invasive ductal
grade 2, ER +ve and PR+ve, HER2 negative
(ie. luminal tumours). High Ki67 > 20% in 1/4
• Triple negative breast cancer uncommon (0.3%)
• HER2+ve disease less common (8.7%) than in
women
Cardoso et al, Ann Oncol 2018; 29:405-417
International Male Breast Cancer Program
• Central pathology review of early stage cancers: 99% ER+ve, 82% PR+ve, 97% AR+ve
• Adjuvant endocrine therapy should be standard but approximately one in four men did not receive
• Breast cancer-specific mortality was higher in men aged < 50 years
Cardoso et al, Ann Oncol 2018; 29:405-417
Adjuvant Endocrine Therapy for
Male Breast Cancer
• Tamoxifen is the recommended adjuvant endocrine therapy for men with breast cancer
• If men have concerning history of thrombosis, concurrent anticoagulation may be an option
• Adjuvant hormonal therapy with an aromatase inhibitor (AI) as monotherapy should not be recommended
• If an adjuvant AI is chosen over tamoxifen, it should be combined with GnRH agonist
Male Breast Cancer
Genetic Considerations
• Most male breast cancer is sporadic but a significant minority will have a germline BRCA mutation � men should be offered genetic counselling/assessment.
• Men with BRCA2 mutation have ~ 7% lifetime risk of breast cancer and also ↑ risk of prostate cancer.
• Men with BRCA1 mutation have ~ 1% lifetime risk of breast cancer.
Male Breast Cancer
Genomics
• PIK3CA mutations less common in male breast
cancer than in female ER+ve breast cancer
• Genomic analysis of 59 male breast cancers
showed increased frequency of somatic
mutations in genes associated with DNA repair
pathways. ? Future therapeutic implications
for those with metastatic disease.
Piscuoglio et al, Clin Can Res 2016
Male Breast Cancer
Future Directions• Men have often been excluded from randomized trials.
• Men with HR+ breast cancer are eligible to participate in phase 3 adjuvant trials (PALLAS, NATALEE) testing addition of CDK4/6 inhibitors to adjuvant endocrine therapy.
(NB. PALLAS allows tamoxifen, NATALEE requires AI + GnRHa)
• Men with breast cancer and BRCA mutations are eligible to participate in phase 3 OLYMPIA trial testing addition of PARP inhibitor olaparib (concurrent with adjuvant endocrine therapy if HR+), after completion of chemotherapy and loco-regional Rx.
(Neo)Adjuvant Endocrine Therapy
in Elderly (Senior) Patients
Breast Cancer and Age
• In Geriatric Oncology, age of 70 years is the most common cut-off for defining elderly
• ~ 40% breast cancer diagnosed > 65 years (in west)
• ~ 20% breast cancer diagnosed > 75 years
• Mean age of population is rising
• Older women under-represented in breast cancer trials
Mean age of global population
is increasing
Figure taken from United Nations World Population P rospectsat http://esa.un.org/unpp/index.asp?panel=2
55
50
45
40
35
30
25
20
15
Year
United States
South Korea
JapanChina
India
Mexico
Pakistan
1950 1960 1970 1980 1990 2000 2010 2020 2030 2040 2050
Med
ian
age
(yea
rs)
Growing population, with high incidence of disease, are
under-represented in clinical trials
Percentage of trial enrolment of patients ≥65 years old
(Southwest Oncology Group [SWOG] 1993–1996)1
1. Hutchins LF, et al. N Engl J Med 1999;341:2061–72. Droz JP, et al. Crit Rev Oncol Hematol 2008;68:S 1–8
Per
cent
age
patie
nts
70
60
50
40
30
20
10
0
Elderly Patients
Significant Variability in Fitness and Co-morbidities
Physically fit and independent ����
Frail needing substantial functional assistance
Elderly PatientsComprehensive Geriatric Assessment (CGA)
Assess comorbidities and functional status
• Provides extra information beyond ECOG Performance Status
• Assists in prediction of treatment toxicity
• Estimation of life expectancy and prognosis
• Particularly relevant if considering chemotherapy
Life expectancy in senior adults: a large variability reflecting health status variability
18
1
4.35.8
7.9
10.8
14.2
2.33.2
4.7
6.7
12.4
9.3
1.52.2
3.3
6.7
4.9
0
5
10
15
20
25
70 years 75 years 80 years 85 years 90 years 95 years
Life
exp
ecta
ncy,
yea
rs
Top 25th percentile ( FIT seniors)
Lowest 25th percentile ( FRAIL seniors)
50th percentile ( MEDIAN life expectancy)
Walter LC et al. JAMA 2001, 285, 2750-2756
Domains
Cognition
Comorbidity
Emotional conditions
Function
Geriatric syndromes
Nutrition
Pharmacy
Socioeconomicconditions
Health statusgroups
ESMO Resource
“before recommending hormonal therapy to elderly patients, the benefits of treatment should be balanced against potential harms and competing risks of morbidity and mortality”
Breast Cancer in Elderly
• Elderly have higher proportion of ER+ve tumours and so can benefit from adjuvant endocrine therapy.
• Elderly on average (but not all) have more indolent cancers (ie. low-intermediate grade, slower growth)
• Adjuvant endocrine therapy particularly relevant in older patients with pT1 N0/Nx ER+ve HER2-negative (luminal) tumours who have de-escalation of loco-regional therapy (ie. no sentinel node biopsy and/or no radiation to conserved breast)
Adjuvant Tamoxifen 5 years vs none: Age > 70 y
EBCTCG, Lancet 2011
Randomized Trials of Adjuvant AI vs another AI
FACE Trial MA.27 TrialLetrozole vs Anastrozole Exemestane vs Anastrozole
Smith et al, J Clin Oncol 2017 Goss et al, J Clin Oncol 2013
(Neo) Adjuvant Endocrine Therapy
in Elderly Patients
• Unless a high-risk breast cancer, it is reasonable to choose between tamoxifen and AI based on toxicities/comorbidities/patient preferences
• Consider
– Risk for thrombo-embolism (tamoxifen worse)
– endometrial cancer (tamoxifen worse)
– Ocular toxicity (tamoxifen)
– Bone health (and dental health) and associated costs
– Pre-existing musculoskeletal complaints (worse on AI)
– Sexual health if remain sexually active (worse on AI)
– Cardiovascular risks (tamoxifen slightly safer)
(Neo)Adjuvant Endocrine Therapy
in Frail Elderly Patients
• Frail elderly patients with operable HR+ breast cancer
may be referred for primary endocrine therapy
because they are “unfit” for surgery
• Oral endocrine therapy can control unresected luminal
breast cancer for a limited time, so this is only
appropriate if life expectancy is short (< 2-3yrs) or in
case of surgery refusal. Resection under local
anaesthetic is also an option (without axillary surgery).
(Neo)Adjuvant Endocrine Therapy
in Elderly Patients
• Cochrane Review of 7 trials comparing surgery
vs. primary endocrine therapy (tamoxifen) for
elderly women with operable breast cancer
• Primary endocrine therapy was significantly
inferior to surgery (+/- endocrine therapy) for
local control of breast cancer ie. worse PFS
(progression-free survival)
http://www.cochrane.org/reviews/en/ab004272.html
(Neo)Adjuvant Endocrine Therapy
in Elderly Patients
• Neoadjuvant endocrine therapy prior to planned surgery is a reasonable option for locally advanced luminal-A like tumours
• Aromatase Inhibitors (AI) were superior to tamoxifen in postmenopausal neoadjuvant trials (P024 and IMPACT trials) and increased likelihood of breast conservation being feasible
• Comparison of 3 different aromatase inhibitors in neoadjuvant setting did not show clear differences (ACOSOG Z1031 trial)
• It often takes > 6 months to reach maximum response with neoadjuvant endocrine therapy
Smith et al, J Clin Oncol 2005Eiermann et al, Ann Oncol 2001 Ellis et al, J Clin Oncol 2011
Invasive Lobular Cancer (ILC)
• 2nd most common histologic subtype after ductal
• Immunhistochemistry (IHC) E-cadherin negative
• Most common is classical lobular which is typically endocrine responsive
• Pleomorphic lobular is more aggressive and chemotherapy often recommended prior to ET
Lobular Breast Cancer
Adjuvant Endocrine Therapy
Metzger-Filho et al, J Clin Oncol 2015
BIG 1-98 Trial Postmenopausal HR+Advantage of AI over Tamoxifen in Invasive Duct (NST)
BIG 1-98 Trial Postmenopausal HR+Advantage of AI over Tamoxifen in Lobular
BIG 1-98 Trial Postmenopausal HR+
BIG 1-98 Trial Postmenopausal HR+
Magnitude of benefit for Letrozole
greater with lobular than ductal
Metzger-Filho et al, J Clin Oncol 2015
Adjuvant Endocrine Therapy in
Very Young Patients
Role of Ovarian Function Suppression
(OFS)
Background: Adjuvant Endocrine Therapy
Premenopausal HR+ Breast Cancer
• Ovarian function suppression or ablation (OFS) maybe
recommended in addition to tamoxifen
• OFS (GnRH) frequently started after chemotherapy is
completed, unless fertility preservation is desired
• The value of adding OFS for premenopausal women
who receive tamoxifen (either with or without prior
chemotherapy) was previously considered uncertain
Adjuvant Ovarian Suppression or Ablation
Effect on Breast Cancer Recurrence (no tamoxifen)
EBCTCG Lancet 2005
RANDOMIZE
Tamoxifen x 5y
OFS=ovarian function suppression(GnRH triptorelin, oophorectomy or irradiation)
3047 Patients Randomized in ITT, Dec 2003 - Jan 2011Median follow-up 5.6 years
SOFTPremenopausal ER+ and/or PR+ Breast Cancer
Exemestane+OFS x 5y
Tamoxifen+OFS x 5y
No Chemotherapy
Prior Chemotherapy
Premenopausal, within 12 weeks of surgery(Median time since surgery = 1.8 months )
Premenopausal* after completing chemotherapy; Randomization within 8 months of completion(Median time since surgery = 8.0 months )
(n=1018)
(n=1015)
Primary Analysis (n= 2033)
Two Patient Cohorts (stratified)
(n=1014)
*According to locally-determined E2 level in premenopausal range
(47%)
(53%)
SOFT
Suppression of Ovarian Function Trial
Primary Question:
Does adding ovarian function suppression (OFS)
improve outcomes in premenopausal women
treated with adjuvant tamoxifen?
SOFT DFS8 years median follow-up
T+OFS significantly improves DFS vs T-alone in the overall population
Tamoxifen
vs ↑ 8 year DFS = 8.7%
Tamoxifen + OFS
vs
Exemestane + OFS ↑ 8 year DFS = 13.1%
SOFT: Disease-Free Survival (DFS)
Very young patients < 35 years
SOFT: Women < 35 years8-year Freedom from invasive breast cancer
SOFT: Women < 35 years
8-year Freedom from distant recurrence
SOFT: Conclusions
• Adding OFS to tamoxifen significantly improves DFS at 8 years median follow-up – HR=0.66 (8.7% absolute benefit) in DFS for women under age 35
– DFS outcomes further improved by use of exemestane plus OFS
• Small (significant) Overall Survival benefit is seen at 8 years– Evident in women with prior chemotherapy
– Consistent with time course of events in ER+ disease
• Population not receiving chemotherapy has a low risk of distant metastases at 8 years with tamoxifen alone
Francis et al, N Engl J Med 2018
SOFT – Young women
Now more likely to recommend ovarian suppression in
women < 35 with HR+ early breast cancer
In young women with chemo-induced amennorhea
if planning to use an AI (exemestane) don’t need to
wait for premenopausal E2 before starting GnRHa, as
cannot guarantee efficacy AI without OFS at young age
In young women, if side effects with exemestane + OFS are
not acceptable, there may still be value in tamoxifen+OFS
over tamoxifen alone.
St Gallen 2017 Early Breast Cancer
International Consensus Panel
• The Panel identified age < 35 and/or involvement of > 4 lymph nodes as factors arguing for inclusion of ovarian function suppression.
• Women with sufficient tumor risk so as to warrant chemotherapy may wish to consider ovarian suppression.
• The Panel believed ovarian suppression could be paired with either tamoxifen or an AI.
Annals Oncology 2017; 28:1700-1712
ASCO 2016 Clinical Practice Guideline Update
on Adjuvant Ovarian Suppression in HR+ve
Burstein et al, J Clin Oncol 2016
ASCO 2016 Guideline Update
Adjuvant Ovarian Suppression in HR+ve
• The Panel recommends that higher-risk patients should receive ovarian suppression in addition to adjuvant endocrine therapy.
• Ovarian suppression may be administered with either tamoxifen or an aromatase inhibitor.
• The Panel particularly encouraged clinicians to consider ovarian suppression in women younger than age 35 years.
Burstein et al, J Clin Oncol 2016
ESO-ESMO 3rd International Consensus Guidelines
for Breast Cancer in Young Women
Paluch-Shimon et al, The Breast 2017;35: 2013-217